{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:51:09Z","timestamp":1792576269587,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019708","name":"UroGen Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.euf.2023.03.016","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T16:02:25Z","timestamp":1681315345000},"page":"807-812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease"],"prefix":"10.1016","volume":"9","author":[{"given":"Kyle M.","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie S.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Labbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hristos","family":"Kaimakliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rian","family":"Dickstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2023.03.016_b0005","unstructured":"United States Food and Drug Administration. Full prescribing information: Jelmyto (mitomycin) for pyelocalyceal solution. Silver Spring, MD: US FDA; 2021. https:\/\/www.urogen.com\/download\/pdf\/jelmyto_prescribing.pdf."},{"key":"10.1016\/j.euf.2023.03.016_b0010","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2023.03.016_b0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0020","doi-asserted-by":"crossref","first-page":"147.e15","DOI":"10.1016\/j.urolonc.2022.10.029","article-title":"Early experience with UGN-101 for the treatment of upper tract urothelial cancer \u2013 a multi-center evaluation of practice patterns and outcomes","volume":"41","author":"Woldu","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2023.03.016_b0025","article-title":"Antegrade administration of mitomycin gel for UTUC via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study","author":"Rose","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.03.016_b0030","article-title":"Efficacy and safety of mitomycin gel (UGN-101) as an adjuvant therapy after complete endoscopic management of upper tract urothelial carcinoma","author":"Labbate","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0035","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.juro.2007.05.056","article-title":"Imperative indications for conservative management of upper tract transitional cell carcinoma","volume":"178","author":"Krambeck","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.23736\/S2724-6051.20.03710-8","article-title":"Conservative treatment of upper urinary tract carcinoma in patients with imperative indications","volume":"73","author":"Proietti","year":"2021","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.euf.2023.03.016_b0045","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0022-5347(05)64454-0","article-title":"Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery","volume":"168","author":"Thalmann","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupret","year":"2021","journal-title":"Eur Urol"},{"issue":"12 Suppl","key":"10.1016\/j.euf.2023.03.016_b0055","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.euf.2023.03.016_b0060","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.euf.2023.03.016_b0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.ju.0000132128.79974.db","article-title":"Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup","volume":"172","author":"Palou","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-5347(01)65854-3","article-title":"Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors","volume":"156","author":"Martinez-Pineiro","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0075","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00345-018-2349-9","article-title":"Salvage topical therapy for upper tract urothelial carcinoma","volume":"36","author":"Balasubramanian","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0080","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1046\/j.1442-2042.2002.00551.x","article-title":"Clinical outcome of bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract","volume":"9","author":"Miyake","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1464-410x.2000.00610.x","article-title":"Bacillus Calmette-Guerin instillation treatment for carcinoma in situ of the upper urinary tract","volume":"85","author":"Nishino","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.03.016_b0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1159\/000020365","article-title":"Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract","volume":"38","author":"Nonomura","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0095","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1046\/j.1464-410X.1996.09559.x","article-title":"Bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract","volume":"77","author":"Yokogi","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.euf.2023.03.016_b0100","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/01.ju.0000147747.89028.64","article-title":"Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation","volume":"173","author":"Yossepowitch","year":"2005","journal-title":"J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923000858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923000858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:54:41Z","timestamp":1762498481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456923000858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2405456923000858"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2023.03.016","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2023.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}